Belzutifan and Lenvatinib Combination Improves Progression Free Survival in Advanced Renal Cell Carcinoma
Trial shows new drug combo slows advanced kidney cancer growth
A Phase 3 trial demonstrates that the belzutifan-lenvatinib combination significantly extends progression-free survival in patients with adv…
A new drug combination helped slow the growth of advanced kidney cancer in patients who did not respond to earlier treatments.
Mezigdomide plus carfilzomib and dexamethasone improves progression-free survival to 18.0 months in multiple myeloma
Trial shows mezigdomide improves progression-free survival in multiple myeloma
This Phase 3 randomized controlled trial of 479 adult patients with measurable multiple myeloma found that mezigdomide plus carfilzomib and …
A new treatment combination involving mezigdomide and carfilzomib significantly extended the time patients lived without their cancer progre…
Combined SHOX2 and RASSF1A methylation provides superior diagnostic performance for lung cancer detection
Combined Biomarkers Show Better Accuracy for Lung Cancer Diagnosis
This meta-analysis of 49 studies evaluates the diagnostic performance of SHOX2 and RASSF1A methylation in lung cancer. The combined methylat…
Combining two specific genetic markers, SHOX2 and RASSF1A, may provide a more accurate way to detect lung cancer than using either one alone…
ctDNA-guided adjuvant immunotherapy improves survival outcomes in patients with muscle-invasive urothelial carcinoma
ctDNA Testing May Help Guide Immunotherapy for Bladder Cancer
Researchers evaluated the impact of ctDNA-guided or ctDNA-stratified adjuvant immunotherapy on patients with muscle-invasive urothelial carc…
New analysis suggests using ctDNA tests to guide immunotherapy for patients with muscle-invasive urothelial carcinoma after surgery.
Tele-robot-assisted prostatectomy achieves 100% technical success in small case series
Remote Robot Prostate Surgery Shows Promise in Early Data
This meta-analysis of small case series found that tele-robot-assisted prostatectomy achieved a 100% technical success rate (80/80) with no …
Remote-controlled robot prostate surgery succeeded in all 80 patients, with no severe complications, but the evidence is early.
DLL3-directed therapy shows early activity in biomarker-selected neuroendocrine prostate cancer cases
New research explores ways to treat neuroendocrine prostate cancer
This narrative review explores the tumor microenvironment (TME) and DLL3-directed therapy in neuroendocrine prostate cancer (NEPC). The revi…
New research looks at how the environment around tumors might help target and treat a specific, aggressive form of prostate cancer.
FDA Approves Ziihera (zanidatamab-hrii) for HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancer
FDA approves new drug Ziihera for two types of cancer
The FDA approved Ziihera (zanidatamab-hrii) for first-line treatment of HER2-positive gastroesophageal adenocarcinoma in combination with ch…
The FDA has approved Ziihera for two HER2-positive cancers: stomach and bile duct. It offers a new targeted treatment option. This approval …
FDA Approves Tevimbra (tislelizumab-jsgr) for Esophageal and Gastric Cancers
FDA approves new drug Tevimbra for two types of stomach and esophagus cancer.
The FDA approved Tevimbra (tislelizumab-jsgr) for first-line treatment of PD-L1-positive unresectable or metastatic esophageal squamous cell…
The FDA approved Tevimbra (tislelizumab-jsgr) for certain esophageal and stomach cancers. It is used alone or with chemotherapy for patients…
Systemic therapies may complicate radiation-induced lung injury by sustaining inflammation or delaying repair
Systemic Treatments May Affect Radiation Lung Injury Recovery
This narrative review examines the management of pulmonary events in patients receiving thoracic radiotherapy and combination anticancer the…
New clinical perspectives help doctors distinguish between radiation damage and complications caused by systemic cancer treatments in lung p…
Bioactive compounds from aromatic plants show potent cytotoxic activities in various preclinical cancer models
Aromatic plants may contain compounds that fight cancer cells
This systematic review examines the anticancer potential of bioactive compounds from underexplored aromatic plants, including monoterpenes a…
Certain compounds found in aromatic plants show promise in lab tests against cancer, but more human trials are needed to confirm their safet…
Splicing-derived neoantigens provide diverse target classes for T-cell and antibody-based cancer immunotherapies
Splicing-Derived Neoantigens Offer New Targets for Cancer Immunotherapy
This systematic review explores splicing-derived neoantigens as potential targets for cancer immunotherapy. The review identifies two major …
New research identifies splicing-derived neoantigens as a promising source of specific targets for T-cell and antibody-based cancer treatmen…
D-VCd improves hematologic CR rate to 59.5% compared to 19.2% in AL amyloidosis
Trial shows adding daratumumab improves outcomes for AL amyloidosis
This Phase 3 randomized controlled trial of 388 patients with newly diagnosed AL amyloidosis found that adding subcutaneous daratumumab to V…
Adding daratumumab to a standard drug combination helps patients with AL amyloidosis achieve faster and deeper responses in blood and organ …